Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Mandala Pharmacon Indonesia
Herliani Herliani
Biology Education Study Program, Faculty of Teacher Training and Education, Mulawarman University, Samarinda
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
In Silico Study of Anti-Inflammatory Activity of Balangla Fruit Compounds (Litsea cubeba) as AKR1C3 Inhibitor Candidates in Osteoarthritis Rusni Ernopita Ulan; Dora Dayu Rahma Turista; Herliani Herliani; Miningsih Miningsih; Risty Geofani; Dorce Bani; Sintya Sintya
Jurnal Mandala Pharmacon Indonesia Vol. 12 No. 1 (2026): Jurnal Mandala Pharmacon Indonesia 
Publisher : Program Studi Farmasi Universitas Mandala Waluya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35311/jmpi.v12i1.1230

Abstract

Osteoarthritis (OA) is a joint disease characterized by thinning of the cartilage and synovial inflammation. Factors contributing to OA include aging, obesity, genetics, and lack of physical activity, with women being more frequently affected than men. This research aims to assess the potential anti-inflammatory activity of Balangla fruit (Litsea cubeba) as a candidate AKR1C3 inhibitor through an in silico approach. Molecular docking analysis was performed using the AKR1C3 receptor (PDB ID: 1S2A). Alpha-Caryophyllene and Beta-Caryophyllene showed the strongest binding affinity of -8.7 kcal/mol and -8.5 kcal/mol, respectively, indicating favorable interactions with the target receptor. Based on Lipinski's rule, it shows that compounds from Balangla fruit (L. cubeba) meet the basic parameters, in addition to showing potential as anti-inflammatory agent candidates for osteoarthritis, these compounds also have good ADME-Tox profiles with relatively low toxicity levels, thus supporting their further development as drug candidates. Therefore, further research through in vitro and in vivo testing is still needed to confirm its safety, effectiveness, and potential safety in clinical applications.
Co-Authors Dora Dayu Rahma Turista Dorce Bani Miningsih Miningsih Risty Geofani Rusni Ernopita Ulan Sintya Sintya